EA201690826A1 - Рекомбинантные гликопротеиды и их применения - Google Patents

Рекомбинантные гликопротеиды и их применения

Info

Publication number
EA201690826A1
EA201690826A1 EA201690826A EA201690826A EA201690826A1 EA 201690826 A1 EA201690826 A1 EA 201690826A1 EA 201690826 A EA201690826 A EA 201690826A EA 201690826 A EA201690826 A EA 201690826A EA 201690826 A1 EA201690826 A1 EA 201690826A1
Authority
EA
Eurasian Patent Office
Prior art keywords
recombinant
galactosidase
methods
human
glycoproteides
Prior art date
Application number
EA201690826A
Other languages
English (en)
Other versions
EA034515B1 (ru
Inventor
Карен Ли
Кристофер Хванг
Кристин Демария
Original Assignee
Джензим Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джензим Корпорейшн filed Critical Джензим Корпорейшн
Publication of EA201690826A1 publication Critical patent/EA201690826A1/ru
Publication of EA034515B1 publication Critical patent/EA034515B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70592—CD52
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

В настоящем изобретении предлагаются рекомбинантные гликопротеиды (например, рекомбинантные белки α-галактозидазы-А человека) с измененным (например, улучшенным) профилем гликозилирования, и фармацевтические композиции и наборы, содержащие один или несколько из таких белков. Также предлагаются способы создания клетки млекопитающего, применимой для экспрессии рекомбинантного гликопротеида (например, рекомбинантной α-галактозидазы-А человека), способы получения рекомбинантных гликопротеидов и способы лечения, которые включают в себя введение субъекту по меньшей мере одного из рекомбинантных гликопротеидов (например, рекомбинантного белка α-галактозидазы-А человека).
EA201690826A 2013-10-23 2014-10-22 Рекомбинантные гликопротеиды и их применения EA034515B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361894879P 2013-10-23 2013-10-23
US201361901942P 2013-11-08 2013-11-08
PCT/US2014/061789 WO2015061464A2 (en) 2013-10-23 2014-10-22 Recombinant glycoproteins and uses thereof

Publications (2)

Publication Number Publication Date
EA201690826A1 true EA201690826A1 (ru) 2016-08-31
EA034515B1 EA034515B1 (ru) 2020-02-14

Family

ID=51871299

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690826A EA034515B1 (ru) 2013-10-23 2014-10-22 Рекомбинантные гликопротеиды и их применения

Country Status (33)

Country Link
US (2) US11208644B2 (ru)
EP (2) EP3778884A1 (ru)
JP (2) JP6837334B2 (ru)
KR (2) KR102298080B1 (ru)
CN (3) CN114606217A (ru)
AU (2) AU2014340152A1 (ru)
BR (1) BR112016008086A2 (ru)
CA (1) CA2927852A1 (ru)
CL (1) CL2016000961A1 (ru)
CR (1) CR20160225A (ru)
DK (1) DK3060660T3 (ru)
DO (1) DOP2016000079A (ru)
EA (1) EA034515B1 (ru)
ES (1) ES2882562T3 (ru)
HR (1) HRP20211197T1 (ru)
HU (1) HUE055236T2 (ru)
IL (2) IL245255B (ru)
LT (1) LT3060660T (ru)
MX (1) MX2016005321A (ru)
MY (2) MY197247A (ru)
NZ (1) NZ720384A (ru)
PE (1) PE20160723A1 (ru)
PH (1) PH12016500708A1 (ru)
PL (1) PL3060660T3 (ru)
PT (1) PT3060660T (ru)
RS (1) RS62171B1 (ru)
SG (2) SG11201602932WA (ru)
SI (1) SI3060660T1 (ru)
TN (1) TN2016000140A1 (ru)
TW (3) TW202332774A (ru)
UA (1) UA119857C2 (ru)
UY (1) UY35794A (ru)
WO (1) WO2015061464A2 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
WO2017201328A1 (en) * 2016-05-18 2017-11-23 Modernatx, Inc. POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE
CA3039673A1 (en) 2016-10-20 2018-04-26 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of fabry disease
TW201829770A (zh) 2017-01-10 2018-08-16 美商阿米庫斯醫療股份有限公司 用於治療fabry氏病之重組α-半乳糖苷酶A

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
EP1538202B1 (en) * 1996-09-13 2014-01-22 Shire Human Genetic Therapies, Inc. Production of human alpha-galactosidase A
JP2002522509A (ja) 1997-10-29 2002-07-23 ジェンザイム・コーポレイション リソソーム貯蔵疾患治療組成物および方法
US20020081654A1 (en) * 2000-04-07 2002-06-27 Sandrin Mauro Sergio Targeting hydrolase enzymes
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7133354B2 (en) 2002-08-26 2006-11-07 Qualcomm Incorporated Synchronization techniques for a wireless system
ES2354610T5 (es) * 2002-12-23 2020-09-14 Bristol Myers Squibb Co Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína
CN100522988C (zh) * 2003-04-09 2009-08-05 诺和诺德公司 糖peg化方法及由该方法生产的蛋白质/肽
EP2134853B1 (en) * 2007-04-03 2018-07-18 Oxyrane UK Limited Glycosylation of molecules
BRPI0815889A2 (pt) * 2007-08-31 2014-10-14 Hoffmann La Roche Análise do perfil de glicosilação.
RU2011142230A (ru) * 2009-04-20 2013-05-27 Пфайзер Инк. Контроль гликозилирования белка и композиции и способы, касающиеся этого
CN102933707B (zh) * 2010-03-02 2015-09-30 普罗塔里克斯有限公司 稳定的α-半乳糖苷酶及其用途
US20120178105A1 (en) 2011-01-10 2012-07-12 Genzyme Corporation Detection of globotriaosylceramide (glc) in human urine samples using an antibody sandwich
DK2665814T3 (en) * 2011-01-20 2017-09-11 Protalix Ltd NUCLEIC ACID CONSTRUCTION FOR EXPRESSION OF ALPHA-GALACTOSIDASE IN PLANTS AND PLANT CELLS
AU2012322811A1 (en) * 2011-10-12 2014-05-01 Synageva Biopharma Corp. Recombinant human NaGlu protein and uses thereof
EP2620506A1 (en) 2012-01-25 2013-07-31 Arla Foods Amba Method of producing a galacto-oligosaccharide-containing composition
TWI528785B (zh) 2013-02-08 2016-04-01 瑞昱半導體股份有限公司 立體影像的調整裝置及其方法
MX2015012114A (es) 2013-03-08 2016-01-12 Genzyme Corp Fabricacion continua integrada de principios activos proteinicos terapeuticos.

Also Published As

Publication number Publication date
US20220064617A1 (en) 2022-03-03
IL272609A (en) 2020-03-31
IL245255B (en) 2020-02-27
US20160264953A1 (en) 2016-09-15
HUE055236T2 (hu) 2021-11-29
PH12016500708A1 (en) 2016-05-30
DOP2016000079A (es) 2016-05-30
IL245255A0 (en) 2016-06-30
EP3060660A2 (en) 2016-08-31
HRP20211197T1 (hr) 2021-11-12
CN112852784A (zh) 2021-05-28
TW202332774A (zh) 2023-08-16
IL272609B (en) 2022-03-01
KR20210111880A (ko) 2021-09-13
WO2015061464A2 (en) 2015-04-30
SG11201602932WA (en) 2016-05-30
JP6837334B2 (ja) 2021-03-03
AU2014340152A1 (en) 2016-06-09
KR102298080B1 (ko) 2021-09-06
TW201900873A (zh) 2019-01-01
UA119857C2 (uk) 2019-08-27
CN114606217A (zh) 2022-06-10
KR102479886B1 (ko) 2022-12-20
EP3060660B1 (en) 2021-06-23
PT3060660T (pt) 2021-08-06
DK3060660T3 (da) 2021-09-13
EP3778884A1 (en) 2021-02-17
SI3060660T1 (sl) 2021-09-30
CN105916984A (zh) 2016-08-31
BR112016008086A2 (pt) 2017-10-03
TWI642782B (zh) 2018-12-01
SG10201803366PA (en) 2018-05-30
TW201610163A (zh) 2016-03-16
RS62171B1 (sr) 2021-08-31
EA034515B1 (ru) 2020-02-14
PE20160723A1 (es) 2016-08-01
JP7296327B2 (ja) 2023-06-22
MY197247A (en) 2023-06-08
JP2020089379A (ja) 2020-06-11
CR20160225A (es) 2016-06-24
PL3060660T3 (pl) 2021-12-06
ES2882562T3 (es) 2021-12-02
LT3060660T (lt) 2021-07-26
KR20160066550A (ko) 2016-06-10
UY35794A (es) 2015-05-29
NZ720384A (en) 2022-04-29
JP2016538840A (ja) 2016-12-15
CL2016000961A1 (es) 2017-02-03
AU2020294173A1 (en) 2021-02-11
WO2015061464A3 (en) 2015-09-03
CA2927852A1 (en) 2015-04-30
MX2016005321A (es) 2017-01-05
MY178632A (en) 2020-10-19
TN2016000140A1 (en) 2017-10-06
TWI793159B (zh) 2023-02-21
US11208644B2 (en) 2021-12-28

Similar Documents

Publication Publication Date Title
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
ZA202201361B (en) Methods and compositions comprising purified recombinant polypeptides
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
EA201890456A1 (ru) Новый слитый полипептид, специфичный в отношении lag-3 и pd-1
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
TR201809571T4 (tr) Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
CY1124778T1 (el) Αντισωματα anti-asic1 και χρησεις αυτων
EA201491644A1 (ru) Фармацевтические композиции
EA201690377A1 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
EA201991409A2 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
MX2019004487A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
MX2015000754A (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
EA201690826A1 (ru) Рекомбинантные гликопротеиды и их применения
MX2020012356A (es) Sobreexpresion de reguladores de la ruta de n-glicosilacion para modular la glicosilacion de proteinas recombinantes.
ECSP20083339A (es) Proteínas inmunodominantes y fragmentos en esclerosis múltiple
BR112016005899A2 (pt) composições compreendendo populações heterogêneas de proteínas de fator xa de coagulação recombinante humano
WO2013109190A3 (en) Cho-gmt recombinant protein expression
EA201992746A2 (ru) Рекомбинантные гликопротеиды и их применения
EA201591832A1 (ru) Коэкспрессия фактора viii и фактора фон виллебранда
AR098154A1 (es) Glicoproteínas recombinantes y sus usos
CY1124859T1 (el) Ομοδιμερικο πεπτιδιο για τη θεραπεια του διαβητη και σχετικων νοσων
AR120358A1 (es) Proteínas cdkl5 recombinantes, terapia génica y métodos de producción

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM